Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

shankar besta

  • Home
  • Author: shankar besta

Trump’s presidency return could boost US biopharmaceutical deal activity, says GlobalData

On 5 November 2024, Donald Trump was elected as the US president for the second term, marking the return of Republican leadership following President Joe Biden’s administration, which saw significant policy changes for the biopharmaceutical industry, such as the Inflation Reduction Act. Although Trump did not disclose his intended healthcare policy changes during his campaign, […]
Read more

NAPCHD’s new guidelines signal shift in type 1 diabetes management for care home residents in UK, says GlobalData

The National Advisory Panel on Care Home Guidance (NAPCHD) has introduced a groundbreaking framework designed to transform type 1 diabetes management in care homes across England. The comprehensive guidance, “Type 1 Diabetes in Care Homes: A Practical Guide on Management,” is aimed at addressing critical challenges in managing diabetes among care home residents. By offering […]
Read more

Japan’s measures to fight climate change to drive innovation in agri-food manufacturing sector, says GlobalData

Due to the escalating impact of climate change on food production, Japan is intensifying to safeguard the quality and sustainability of its food supply. The nation is rolling out innovative measures to address the challenges posed by unpredictable weather patterns, rising temperatures, and extreme natural disasters, which are increasingly threatening agricultural yields and food security. […]
Read more

Legal and ethical challenges shaping AI-driven clinical trials, says GlobalData

The integration of artificial intelligence (AI) in clinical trials has transformed healthcare by enhancing data analysis, predicting outcomes, and expediting drug development. However, this innovation comes with significant legal and ethical challenges, as AI systems rely heavily on vast datasets from clinical trials, raising concerns about consent, data origin, and ethical standards, says GlobalData, a […]
Read more

Unifying political framework will unlock full potential of AI-driven healthcare, says GlobalData

Artificial Intelligence (AI) has revolutionized healthcare, enhancing diagnostics, personalizing treatments, and improving patient outcomes. The rapid adoption of AI has led to a fragmented regulatory landscape in the US. Many states have introduced AI-specific legislation addressing data privacy and cybersecurity. For instance, states like California have enacted stringent consumer protection laws limiting personal data use, […]
Read more

AstraZeneca’s AZD4041 failure major blow for non-opioid medications treating opioid addiction, says GlobalData

Opioid use disorder (OUD) is a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, leading to prolonged self-administration. AstraZeneca recently terminated the development of an OUD drug, AZD4041, after the orexin 1 receptor antagonist demonstrated a drug-drug interaction with an antifungal during a Phase II trial. The failure of the trial […]
Read more

Arteriotomy closure devices market to reach $873 million by 2033, forecasts GlobalData

The rise in cardiovascular diseases globally has resulted in a higher number of interventional procedures, necessitating the use of arteriotomy closure devices. Arteriotomy closure devices are essential in managing access sites after procedures such as angiography or vascular interventions. Valued at $641 million in 2024, the arteriotomy closure devices market is projected to reach sales […]
Read more

Digital transformation to help accelerate drug development and discovery process, says GlobalData

Ever increasing drug discovery and development timelines is a multiscale issue causing delays in patient access to medicines and increasing costs for pharmaceutical companies. Digital transformation could streamline the process, accelerate innovation, and improve efficiency, according to a survey conducted by GlobalData, a leading data and analytics company. In a recent GlobalData’s survey, “Digital Transformation […]
Read more

AI regulation future in US remains uncertain, says GlobalData

In November 2024, Donald Trump was re-elected as President of the US, with Elon Musk appointed to lead the newly established Department of Efficiency. Musk’s role focuses on streamlining government processes and integrating advanced technologies, a development that marks a significant shift in the regulatory landscape for artificial intelligence (AI) and other emerging technologies. However, […]
Read more

RFK Jr.’s appointment as US HHS Secretary to reshape regulatory and market landscape of medical devices, says GlobalData

The appointment of Robert F. Kennedy Jr. as Secretary of Health and Human Services (HHS) has raised significant discussion in the healthcare sector. Healthcare officials have voiced concerns, particularly regarding Kennedy’s history of spreading misinformation and his controversial stance on vaccines. He may advocate for greater scrutiny of medical device approvals, reflecting his general skepticism […]
Read more

Premier League clubs banning associated party transactions to change football league’s sponsorship landscape, says GlobalData

Following the news that Premier League teams have banned associated party transactions; Conrad Wiacek, Head of Sport Analysis at GlobalData, a leading data and analytics company, offers his view: “The decision by Premier League clubs to ban associated party transactions (APT) will be felt by several clubs across the football league. Premier League teams generate […]
Read more
1 … 55 56 57 58 59 … 136